Medidata's Engage Wins Patient Engagement App Challenge
Medidata's Engage won the Patient Engagement App Challenge (large organization category) at the 23rd Annual Partnerships in Clinical Trials Conference.
Medidata's Engage won the Patient Engagement App Challenge (large organization category) at the 23rd Annual Partnerships in Clinical Trials Conference.
The app prototype is billed as an easy-to-use, device-agnostic app that patients can access via their personal smartphones or other mobile devices.
A team of Medidata engineers developed Engage during company-sponsored innovation time, a program Medidata put in place that allows employees to think creatively about solving problems and use technology in different ways. Engage creates new connections between patients, physicians and sponsors, and is built to work with Medidata Patient Cloud™, a solution for patient-centric data capture and management.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
